Skip to content
OpenCapital
Get started
UroGen Pharma logo

UroGen Pharma (URGN) Q1 2026 Earnings

URGN·Reported May 6, 2026·Before market open

UroGen Pharma reported Q1 2026 revenue of $51.0M (+151.6% YoY), beat analyst consensus of $44.8M by $6.1M. Diluted EPS came in at $-0.47 (+48.9% YoY), beat the $-0.56 consensus by $0.09.

Revenue
$51.0Mbeat by $6.1M
Consensus: $44.8M
Diluted EPS
$-0.47beat by $0.09
Consensus: $-0.56
SEC

SEC Filings

Earnings release8-K · 0001437749-26-015018
Quarterly report10-Q · 0001437749-26-015019

Financial Snapshot

Trailing eight quarters through Q1 2026

View all metrics

Q1 2026 Earnings FAQ

Common questions about UroGen Pharma's Q1 2026 earnings report.

UroGen Pharma (URGN) reported Q1 2026 earnings on May 6, 2026 before market open.

UroGen Pharma reported revenue of $51.0M and diluted EPS of $-0.47 for Q1 2026.

Revenue beat the consensus estimate of $44.8M by $6.1M. EPS beat the consensus estimate of $-0.56 by $0.09.

Compared to the same quarter a year prior, revenue grew 151.6% from $20.3M a year earlier and diluted EPS grew 48.9% from $-0.92.

You can read the 8-K earnings release (0001437749-26-015018) and the 10-Q periodic report (0001437749-26-015019) directly on SEC EDGAR. The filing index links above go to sec.gov.